Recon: Congress reaches deal on $10B COVID bill; Gilead’s remdesivir fails to show benefit in European trial
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy